Roche Holding sets July half-year results date, analysts keep a clear view on the shares

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 13:50.

Roche Holding (CH0012032048) has invited investors to its Half Year Results 2026 presentation, scheduled for Thursday 23 July 2026 before the opening of SIX Swiss Exchange trading in Zurich, according to the group’s investor update of 23 June 2026.Roche investor update on the half-year results presentation The pharma and diagnostics group will release figures at 07:00 CEST, followed by a management webinar with Q&A later the same day.

What Roche has announced

The company plans to publish its Half Year Results 2026 on 23 July 2026 at 07:00 CEST, with the release e-mailed to subscribers and posted on the Roche investor relations website, as the invitation details.Official invitation to the Half Year Results 2026 presentation Management presentations and a webcast Q&A are scheduled between 14:00 and 15:45 CEST, offering institutional and retail investors a structured update on strategy and performance.

The invitation lists investor contacts including Dr. Bruno Eschli, Dr. Sabine Borngräber and Dr. Birgit Masjost for Europe, as well as Loren Kalm for the US, underlining the global investor base of the Basel-based SMI constituent.Roche IR contact information in the invitation The upcoming half-year disclosure will be one of the key events for the Swiss large-cap healthcare sector in the third quarter.

Consensus picture on the Roche shares

Analyst data for Roche Holding participation shares compiled by Investing.com show a consensus Buy rating from 18 analysts, with nine Buy, seven Hold and two Sell recommendations.Investing.com consensus data for Roche Holding participation shares The average 12-month price target sits at 358.83 CHF, with a high estimate of 428 CHF and a low estimate of 230 CHF, implying around 10.55 percent upside potential from current levels.

Roche shares most recently traded around 324.70 CHF on SIX Swiss Exchange, according to finanzen.net, giving the group a large-cap market valuation in the Swiss Market Index healthcare segment.Finanzen.net quote page for Roche on SIX Swiss Exchange The Swiss blue-chip stands alongside sector peers such as Novartis and Sanofi in the European pharmaceuticals universe, where defensive cash flows and dividend stability are closely watched.

The product behind the Roche stock

Roche generates a large share of its revenue with prescription medicines in oncology, immunology and neuroscience, complemented by a substantial diagnostics division that supplies laboratory instruments and test kits worldwide.Roche business overview in pharmaceuticals and diagnostics Flagship cancer therapies and innovative biologics sit alongside molecular and point-of-care diagnostic systems, forming a diversified healthcare portfolio.

Where the Roche shares trade today

The Roche Holding shares (CH0012032048) trade on 2026-06-23, 13:30 on SIX Swiss Exchange at approximately 324.70 CHF.

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any transaction. All data are based on sources deemed reliable but may be subject to change. Investors should conduct their own research or consult a qualified advisor before making investment decisions.